Skip to content

Tricuspid Regurgitation in the ElderlY

Prevalence, Mechanisms, and Outcome of Tricuspid Valve Regurgitation in the Elderly

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05784883
Acronym
TREY
Enrollment
700
Registered
2023-03-27
Start date
2022-08-01
Completion date
2029-08-01
Last updated
2025-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tricuspid Regurgitation

Keywords

Valvular heart disease, Tricuspid regurgitation, Elderly, Geriatric, Echocardiography

Brief summary

Tricuspid regurgitation (TR) is the second most common VHD after MR. Its prevalence also increases with age, with an estimated incidence of up to 6% in elderly population. When adjusted to age (among other confounders), survival is worse for patients with moderate and severe TR. We aim to explore the prevalence, mechanisms, and clinical implications of tricuspid valve regurgitation in elderly subjects screened at a tertiary center in Cairo, Egypt.

Interventions

DIAGNOSTIC_TESTEchocardiography

A comprehensive 2- and 3-dimensional transthoracic echocardiography (TTE) assessment of the tricuspid valve and right side of the heart at baseline.

Sponsors

Al-Azhar University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All comer patients ≥60-year-old presenting to the echocardiography clinic

Exclusion criteria

* Poor acoustic window.

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of tricuspid valve regurgitation in the elderlyBaseline (at enrolment)Prevalence of mild, moderate, and severe TR in enrolled patients
All-cause mortalityAt 6 monthsIncidence of death from any cause
Cardiovascular mortalityAt 6 monthsIncidence of cardiovascular death, defined as death attributable to myocardial ischemia and infarction, heart failure, cardiac arrest because of other or unknown cause, or cerebrovascular accident.
Rehospitalization for congestive heart failureAt 6 monthsIncidence of new-onset or worsening signs and symptoms of heart failure that required urgent therapy and resulted in hospitalization.

Secondary

MeasureTime frameDescription
Classification of tricuspid valve regurgitation in the elderlyBaselineClassify the type of TR according to the main morphologic and/or functional abnormality. The classification will be done according to the following proposal, the TR could be 1- primary (organic) if there is an anatomical abnormality of the tricuspid valve apparatus. 2- secondary (functional) if the tricuspid valve apparatus was normal but the TR due to annular dilation. If the annular dilation is due to right ventricular volume or/and pressure overload, the TR will classify as ventricular TR, whereas if the annular dilation is due to atrial fibrillation, the TR will classify as atrial TR. The last type of TR is due to the implantation of a cardiac implantable electronic device (CIED) which will classify as CIED-related TR.
Rehospitalization for congestive heart failureAt 12 and 60 monthsIncidence of new-onset or worsening signs and symptoms of heart failure that required urgent therapy and resulted in hospitalization.
Change in New York Heart Association (NYHA) functional classAt 6, 12 and 60 monthsNew York Heart Association \[NYHA\] functional class (I-IV) will be assessed in all participants at baseline and at follow-up visits (or by phone interviews). NYHA Class I: No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. NYHA Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. NYHA Class III: Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest. NYHA Class IV: Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.
All-cause mortalityAt 12 and 60 monthsIncidence of death from any cause
Cardiovascular mortalityAt 12 and 60 monthsIncidence of cardiovascular death, defined as death attributable to myocardial ischemia and infarction, heart failure, cardiac arrest because of other or unknown cause, or cerebrovascular accident.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 11, 2026